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Abstract
Background: Multi-drug resistance of Gram-negative bacteria constitutes a major obstacle in the antibacterial fight
worldwide. The discovery of new and effective antimicrobials and/or resistance modulators is necessary to combat
the spread of resistance or to reverse the multi-drug resistance. In this study, we investigated the antibacterial and
antibiotic-resistance modifying activities against 29 Gram-negative bacteria including multi-drug resistant (MDR)
phenotypes of the methanol extracts from Nauclea pobeguiinii leaves (NPL), Nauclea pobeguiinii bark (NPB) and six
compounds from the bark extract, identified as 3-acetoxy-11-oxo-urs-12-ene (1), p-coumaric acid (2), citric acid
trimethyl ester (3), resveratrol (4), resveratrol β-D-glucopyranoside (5) and strictosamide (6).
Methods: The broth microdilution method was used to determine the minimal inhibitory concentrations (MIC) and
minimal bactericidal concentrations (MBC) of crude extracts and compounds as well as the antibiotic-resistance
modifying effects of MPB and 4.
Results: MIC determinations indicate values ranging from 32-1024 μg/mL for NPB and NPL on 89.7 % and 69.0 %
of the tested bacterial strains respectively. MIC values below 100 μg/mL were obtained with NPB against Escherichia
coli ATCC10536, AG100 and Enterobacter aerogenes CM64 strains. The lowest MIC value for crude extracts of
32 μg/mL was obtained with NPB against E. coli ATCC10536. Compound 4 was active all tested bacteria, whilst 1, 3
and 6 displayed weak and selective inhibitory effects. The corresponding MIC value (16 μg/mL) was obtained with
4 against Klebsiella pneumoniae KP55 strain. Synergistic effects of the combination of NPB with chloramphenicol
(CHL), kanamycin (KAN) as well as that of compound 4 with streptomycin (STR) and ciprofloxacin (CIP) were
observed.
Conclusion: The present study provides information on the possible use of Nauclea pobeguinii and compound 4 in
the control of Gram-negative bacterial infections including MDR phenotypes. It also indicates that NPB and 4 can
be used as naturally occurring antibiotic-resistance modulators to tackle MDR bacteria.
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Background
Bacterial multi-drug resistance (MDR) constitutes a
major impediment to antibiotherapy worldwide. Over-
expression of tripartite efflux pumps of resistance–nodu-
lation–cell division (RND) family such as AcrAB-TolC
in enterobacteria or MexAB-OprM in Pseudomonas aer-
uginosa have been reported as one of the major mechan-
ism of MDR in Gram-negative bacteria [1, 2]. High rates
of resistance of Gram-negative bacteria to commonly
used antibiotics has been previously reported in
Cameroon [3]. Medically important enterobacteria over-
expressing efflux pumps include various species such as
Escherichia coli, Klebsiella pneumoniae, Enterobacter
aerogenes, Enterobacter cloacae, Providencia stuartii,
Salmonella typhi [4, 5]. The scarcity of the development
of new antibiotics propels development of alternative
medicine including phytotherapy. In fact, medicinal
plants represent a good source of antimicrobials, in
regards to the diversity of their secondary metabolites
[6, 7]. African flora is very rich and has shown a good
potential to fight various human ailments [8]. Therefore,
exploring African flora for antibacterial drug discovery
appears as an attractive strategy. In the past, several me-
dicinal plants of the continent showed good antibacterial
activities against MDR Gram-negative (MDRGN) bacter-
ial species. Some of the most prominent plants include
Dichrostachys glomerata, Beilschmiedia cinnamomea,
Combretum molle [9, 10], Piper nigrum and Telfairia
occidentalis [11], Beilschmedia acuta [12] and Dorstenia
psilurus [13]. Also, several compounds isolated from
African plants displayed good inhibitory effects against
MDRGN. Amongst these are pomolic acid [14], neoba-
vaisoflavone [15], plumbagin, 4-hydroxylonchocarpin [4]
and 5′-methoxyhydnocarpin [16]. The discovery of ef-
flux pump inhibitors (EPIs) is a good alternative to com-
bat MDRGN [17]. EPI generally interact with specific
efflux pump proteins to restore the susceptibility of
MDR bacteria to antibiotics [18]. The search of EPI phy-
tochemicals that can restore the activity of antibiotics
also increase the possibilities to overcome MDR pheno-
types. In the past, numbers of plants extracts and de-
rived molecules have been able to potentiate the activity
of various classes of antibiotics against MDR bacteria
[16, 19–21]. In our continuous quest of naturally occur-
ring bioactive products to tackle bacterial multi-drug re-
sistance, the present study was designed to evaluate the
antibacterial activity of methanol extracts and com-
pounds from Nauclea pobeguinii (Pobég. ex Pellegr.)
Merr. ex E.M.A. (Rubiaceae) against a panel of 29 bac-
teria including MDR phenotypes. The study was ex-
tended to the evaluation of the ability of the studied
samples to restore the activity of commonly used antibi-
otics towards MDR strains. Nauclea pobeguinii is used
in traditional medicine as abortive and for the treatment
of stomach ache, infectious diseases [22], jaundice [23],
fever, diarrhea, worm, and malaria [24]. Recently, the
plant was shown to have cytotoxic effects on various
hematological and carcinoma cell lines [25]. Previous
phytochemical investigation of the plant led to the isola-
tion of compounds identified as 3-acetoxy-11-oxo-urs-
12-ene (1), p-coumaric acid (2), citric acid trimethyl
ester (3), resveratrol (4), resveratrol β-D-glucopyranoside
(5) and strictosamide (6) [25]. The antimalarial efficacy
of stem bark extract of Nauclea pobeguinii in human
adult volunteers with diagnosed uncomplicated falcip-
arum malaria was also reported [26].
Fig. 1 Chemical structures of the compounds isolated from Nauclea pobeguinii. 1: 3-acetoxy-11-oxo-urs-12-ene; 2: p-coumaric acid; 3: citric acid
trimethyl ester; 4: resveratrol; 5: resveratrol β-D-glucopyranoside; 6: strictosamide
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Methods
Plant material and extraction
The leaves and bark of Nauclea pobeguinii was collected
in March and April 2013 at Mbouda (West Region of
Cameroon). The plant was identified at the National
Herbarium in Yaoundé, Cameroon and compared with
voucher formerly kept under the registration number
32597/HNC. Each plant part was air dried and then
powdered. The obtained powder (200 g) was extracted
with methanol (MeOH; 1 L) for 48 h at room
temperature with momentary shaking. Methanol was
then removed under reduced pressure to give residues
which constituted the crude bark (NPB) and leaves
(NPL) extracts. All extracts were then kept at 4 °C until
further use.
Chemicals for antimicrobial assay
Compounds previously isolated from the bark of Nau-
clea pobeguinii included 3-acetoxy-11-oxo-urs-12-ene
(1), p-coumaric acid (2), citric acid trimethyl ester (3),
resveratrol (4), resveratrol β-D-glucopyranoside (5) and
strictosamide (6) (Fig. 1). Their isolation and identifica-
tion were previously reported [25]. Tetracycline (TET),
cefepime (CEP), ciprofloxacin (CIP), chloramphenicol
(CHL), ampicillin (AMP), streptomycin (STR), kanamy-
cin (KAN) (Sigma-Aldrich, St Quentin Fallavier, France)
were used as reference antibiotics (RA). p-Iodonitrotetra-
zolium chloride (INT; Sigma-Aldrich) and Phenylalanine-
Arginine-ß-Naphthylamide (PAßN; Sigma-Aldrich) were
used as microbial growth indicator and efflux pumps in-
hibitor (EPI) respectively [27, 28].
Microbial strains and culture media
The studied microorganisms included sensitive and re-
sistant strains of Escherichia coli (ATTC8739,
ATCC10536, AG100, AG100A, AG102, AG100ATet,
MC4100, W3110), Enterobacter aerogenes (ATCC13048,
EA3, EA289, EA294, EA27, EA298, CM64), Klebsiella
pneumoniae (ATCC11296, KP55, KP63, K2, K24),
Pseudomonas aeruginosa (PA01, PA124), Providencia
stuartii (ATCC29914, NEA16, PS299645, PS2636) and
Enterobacter cloacae (BM47, BM67, ECCI69) obtained
clinically or from the American Type Culture Collection
(ATCC). Their resistance profiles have been previously
reported (see Additional file 1: Table S1). Nutrient agar
were used for the activation of the tested Gram-negative
bacteria [29].
INT colorimetric assay for MIC and MBC determinations
The MIC and MBC determinations on the tested bac-
teria were conducted using rapid p-iodonitrotetrazolium
chloride (INT) colorimetric assay according to described
methods [27] with some modifications [30–32].
To evaluate the antibiotic-potentiating effects, a
preliminary study was carried out with 7 antibiotics
(AMP, CEF, CHL, CIP, KAN, STR and TET) and sam-
ples from Nauclea pobeguinii (NPB, NPL, compounds
1–4) against one of the most probematic bacterial
Table 1 MIC and MBC (μg/mL) of Nauclea pobeguinii extracts
and chloramphenicol on the panel of tested bacteria
Bacterial
strains
Tested samples, MIC and MBC (μg/mL)
NPB NPL CHL
Escherichia coli
ATCC8739 512 (>1024) 128 (>1024) 8 (256)
ATCC10536 32 (1024) 256 (>1024) 16 (32)
W 3110 1024 (>1024) >1024 64 (128)
MC4100 256 (>1024) 256 (>1024) 128 (128)
AG100 A 1024 (>1024) 1024 (>1024) 64 (64)
AG100Atet 256 (256) 512 (1024) 64 (128)
AG102 1024 (>1024) 512 (>1024) 64 (64)
AG100 64 (256) 512 (>1024) 16 (64)
Enterobacter aerogenes
ATCC13048 1024 (>1024) 1024 (>1024) 8 (32)
EA294 1024 (>1024) >1024 16 (128)
CM64 1024 (>1024) >1024 128 (>256)
EA298 64 (1024) 1024 (1024) 256 (>256)
EA27 512 (>1024) 256 (>1024) >256
EA289 >1024 1024 (>1024) 256 (>256)
EA3 512 (>1024) 1024 (>1024) >256
Klebsiella pneumoniae
ATCC11296 256 (>1024) 256 (>1024) 8 (256)
KP55 128 (>1024) 128 (>1024) 32 (128)
KP63 1024 (>1024) 256 (>1024) 128 (>256)
K2 512 (>1024) >1024 64 (256)
K24 1024 (>1024) 512 (>1024) 32 (256)
Pseudomonas aeruginosa
PA01 >1024 1024 (>1024) 128 (>256)
PA124 1024 (>1024) >1024 256 (>256)
Providencia stuartii
ATCC29916 1024 (>1024) >1024 16 (32)
PS2636 512 (1024) >1024 32 (32)
PS299645 1024 (>1024) 512 (1024) 32 (256)
NEA16 512 (>1024) 512 (>1024) 256 (>256)
Enterobacter cloacae
BM47 1024 (>1024) >1024 256 (>256)
ECCI69 256 (512) 512 (1024) >256
BM67 >1024 >1024 256 (>256)
The Tested extract were obtained from the bark (NPB) and leaves (NPL); Values
in bold; significant activity
CHL chloramphenicol, MIC Minimal Inhibitory Concentration, MBC Minimal
Bactericidal Concentration
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strains, P. aeruginosa PA124 (see Additional file 1:
Table S2 and S3). Results allowed selecting NPB, NPL
and 4 and their antibiotic-potentiating effects were
further evaluated. Hence, extracts (NPB and NPL)
and compound 4 were tested in association with anti-
biotics at their sub-inhibitory concentrations (MIC/2
and MIC/4) as obtained in each bacterium [9, 11, 13]
respectively against 7 and 6 bacterial strains. Frac-
tional inhibitory concentration (FIC) was calculated as
the ratio of MICAntibiotic in combination/MICAntibiotic alone
and the results were discussed as follows: synergy
(≤0.5), indifferent (>0.5 to 4), or antagonism (>4) [33, 34].
All assays were performed in triplicate.
Results
Compounds tested in this study included 3-acetoxy-
11-oxo-urs-12-ene (1; purity: 90 %), p-coumaric acid
(2; purity: 97 %), citric acid trimethyl ester (3; purity:
97 %), resveratrol (4; purity: 98 %), resveratrol β-D-
glucopyranoside (5; purity: 95 %), and strictosamide
(6; purity: 96 %) previously isolated in the bark of
Nauclea pobeguinii [25]. The antibacterial activity of
these compounds as well as the crude extracts was
evaluated in a panel of Gram-negative bacteria includ-
ing MDR phenotypes. The results are summarized in
Tables 1 and 2.
MIC results as compiled in Table 1 indicate that values
ranging from 32-1024 μg/mL were obtained with NPB
and NPL respectively on 26/29 (89.7 %) and 20/29
(69.0 %) of the tested bacterial strains. The lowest MIC
value of 32 μg/mL was recorded with NPB against
Escherichia coli ATCC10536. Table 2 reports the MIC
values of compounds from NPB. It’s appears that 4 was
active on all the ten selected bacteria including ATCC
strains and clinical MDR phenotypes, whilst 1, 3 and 6
displayed poor and selective inhibitory effects. Com-
pounds 2 and 5 were not active on all tested microor-
ganisms. The lowest MIC value for compound (16 μg/mL)
was obtained with 4 against Klebsiella pneumoniae KP55
strain. The best extract (NPB) as well as the most active
compound (4) had low bactericidal activities, displaying
MBC values only against 6/29 (20.7 %) and 5/10 (50 %) of
the tested pathogens respectively.
Seven antibiotics used in bacterial chemotherapy were
combined with NPB, NPL, compounds 1–4 and tested
in a preliminary study against the problematic nosocomial
pathogen, P. aeruginosa PA124. The results (Additional
file 1: Table S2 and S3) indicated that there was no im-
provement of the activity of the two beta-lactamines
tested (CEF and AMP). Consequently, CEF and AMP as
well as compounds 1–3 having low antibiotic-potentiating
activity against PA124 were not further investigated. Five
antibiotics (CIP, TET, KAN, STR and CHL) were com-
bined with NPB, NPL and compound 4 at their MIC/2
and MIC/5, as obtained on each of the tested bacterial
strains (Tables 3 and 4). At MIC/2 of the samples, NPB
and 4 (6/6) had synergistic effects with CHL and KAN on
100 % tested MDR bacteria. At MIC/4, 100 % synergistic
effects were also obtained when NPB was combined with
STR (Table 3) and when 4 was associated with STR and
CIP (Table 4). NPL had lower synergistic effects with anti-
biotic at MIC/2 and MIC/4.
Table 2 MICs and MBCs (μg/mL) of compounds from Nauclea pobeguinii against selected bacterial strains
Bacterial strains Compounds, MIC and MBC (in bracket)
1 2 3 4 5 6
Escherichia coli
ATCC8739 256 (>256) >256 >256 64 (64) >256 >256
AG100Atet >256 >256 >256 128 (256) >256 >256
AG102 >256 >256 1024 (>256) 32 (32) >256 >256
Enterobacter aerogenes
CM64 >256 >256 >256 64 (>256) >256 >256
Klebsiella pneumoniae
ATCC11296 >256 >256 >256 64 (>256) >256 >256
KP55 >256 >256 32 (128) 16 (32) >256 256 (>256)
Pseudomonas aeruginosa
PA01 >256 >256 >256 64 (128) >256 256 (>256)
PA124 >256 >256 >256 256 (>256) >256 >256
Providencia stuartii
ATCC29916 >256 >256 >256 128 (>256) >256 >256
PS2636 >256 >256 >256 256 (>256) >256 >256
1: 3-acetoxy-11-oxo-urs-12-ene; 2: p-coumaric acid; 3: citric acid trimethyl ester ; 4: resveratrol; 5: resveratrol β-D-glucopyranoside; 6: strictosamide
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Discussion
MDR resistant bacteria of the family enterobacteriaceae
or as well as the nosocomial pathogen Pseudomonas aer-
uginosa are largely involved clinically in treatment fail-
ures [35]. Clinical bacteria used in the present study
actively express efflux pumps [5, 9, 35, 36] and therefore
represent good models in the search of chemicals to
combat drug resistance. Phytochemicals are routinely
classified as significantly active antibacterial agents on
the basis of their MIC values below 100 μg/mL for crude
extracts or 10 μg/mL for compounds; the activity is con-
sidered moderate when 100 <MIC < 625 μg/mL (crude
extracts) or 10 <MIC < 100 μg/mL for molecules [37–39].
Taking in account these cutoff points, it can be deduced
that NPB had a good antibacterial potential, as MIC values
below 100 μg/mL were obtained with this extract against
E. coli ATCC10536, AG100 and Enterobacter aerogenes
CM64 strains. In addition, the MIC value of 64 μg/mL ob-
tained with NPB against E. aerogenes EA298 strain was
lower than that of the reference drug CHL (256 μg/mL).
Nonetheless, compounds 1–6 (from NPB) rather had
moderate, low or no inhibitory effects, suggesting that
they may act synergistically in NPB. However, the lowest
MIC value of 16 μg/mL obtained with 4 was better than
that of CHL (32 μg/mL) against K. pneumoniae KP55
strain, also highlighting the possible usefulness of this




Bacterial strainsb, MIC (μg/mL ) of antibiotics in the absence and presence of the extract and FIC
(in brackets)
PBSS (%)
PA124 CM64 NAE16 BM47 KP55 KP63 AG100Atet
CHL 0 256 128 256 256 32 128 64
B MIC/2 128(0.5)S 64(0.5)S 32(0.125)S 16(0.06)S 16(0.5)S 8(0.06)S 32(0.5)S 7/7 (100 %)
MIC/4 128(0.5)S 64(0.5)S 32(0.13)S 16(0.06)S 32(1)I 8(0.06)S 32(0.5)S 6/7 (85.7 %)
L MIC/2 256(1)I 128(1)I 16(0.06)S 32(0.13)S 32(1)I 8(0.06)S 16(0.25)S 4/7 (57.1)
MIC/4 256(1)I 128(1)I 16(0.06)S 64(0.25)S 32(1)I 8(0.06)S 16(0.25)S 4/7 (57.1)
KAN 0 128 64 64 32 64 64 32
B MIC/2 64(0.5)S 4(0.06)S 8(0.13)S 4(0.13)S 32(0.5)S 8(0.13)S 16(0.5)S 7/7 (100 %)
MIC/4 64(0.5)S 4(0.06)S 8(0.13)S 4(0.13)S 32(0.5)S 8(0.13)S 16(0.5)S 7/7 (100 %)
L MIC/2 64(0.5)S 4(0.06)S 8(0.13)S 4(0.13)S 64(1)I 16(0.25)S 16(0.5)S 6/7 (85.7 %)
MIC/4 64(0.5)S 4(0.06)S 8(0.13)S 4(0.13)S 64(1)I 16(0.25)S 16(0.5)S 6/7 (85.7 %)
STR 0 64 64 32 16 64 16 128
B MIC/2 64(1)I 4(0.06)S 16(0.5)S 4(0.25)S 32(0.5)S 2(0.13)S −(≥2)na 5/6 (83.3 %)
MIC/4 256(4)A 4(0.06)S 16(0.5)S 4(0.25)S 32(0.5)S 8(0.5)S −(≥2)na 5/6 (83.3 %)
L MIC/2 256(4)A 2(0.03)S 8(0.25)S 2(0.13)S 16(0.25)S 4(0.25)S 128(1)I 5/7 (71.4 %)
MIC/4 256(4)A 4(0.06)S 16(0.5)S 4(0.25)S 64(1)I 4(0.25)S −(≥2)na 4/6 (66.7 %)
CIP 0 64 16 8 16 16 8 64
B MIC/2 32(0.5)S 64(4)A 8(1)I 8(0.5)S 16(1)I 4(0.5)S 64(1)I 3/7 (42.9 %)
MIC/4 32(0.5)S 64(4)A 8(1)I 16(1)I 32(2)A 8(1)I 64(1)I 1/7 (14.3 %)
L MIC/2 64(1)I 64(4)A 16(2)A 16(1)I 16(1)I 4(0.5)S 64(1)I 1/7 (14.3 %)
MIC/4 64(1)I 64(4)A 16(2)A 16(1)I 16(1)I 4(0.5)S 64(1)I 1/7 (14.3 %)
TET 0 64 64 128 32 32 64 256
B MIC/2 32(0.5)S 4(0.06)S 32(0.25)S 16(0.5)S 64(2)I 32(0.5)S 4(0.02)S 6/7 (85.7 %)
MIC/4 32(0.5)S 2(0.03)S 32(0.25)S 16(0.5)S 64(2)I 64(1)I 4(0.02)S 5/7 (71.4 %)
L MIC/2 64(1)I 2(0.03)S 128(1)I 32(1)I −(≥8)A 64(1)I 4(0.02)S 2/7 (28.6 %)
MIC/4 64(1)I 2(0.03)S 128(1)I 32(1)I −(≥8)A 64(1)I 4(0.02)S 2/7 (28.6 %)
(−): >256 μg/mL; 0: no extract (only antibiotic tested); na: non-applicable; Values in bold: MIC of antibiotic alone and significant synergistic effects
S Synergy; I Indifference, A Antagonism, B bark extract, L Leaves extract, FIC fractional inhibitory concentration
aAntibiotics [CHL: chloramphenicol, AMP : ampicillin, CEF: cefepime, KAN : kanamycin, STR: streptomycin, CIP : ciprofloxacin, TET : tetracycline]
bBacterial strains: Escherichia coli [ AG100Atet], Pseudomonas aeruginosa [PA124], Enterobacter aerogenes [CM64], Enterobacter cloacae [BM47], Klebsiella
pneumoniae [KP55, KP63], Providencia stuartii [NAE16]
cPBSS: percentage of bacteria strain on which synergism has been observed; (): fold increase in MIC values of the antibiotics after association with plants extract
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compound in the fight against MDR bacteria. It is worth
noting that compound 5 (a glucoside of 4) was not active
contrary to its aglycon 4, indicating that the presence of
glucose in compound 5 significantly reduces its antibac-
terial activities.
Reversal of multi-drug resistance appears today as an-
other attempt to mitigate the spread of resistance in bac-
teria. In recent years, many botanicals showed
antibiotic-modulation effect in efflux pumps over-
expressing MDR bacteria [9, 10, 16, 19, 20, 40–42]. In
the present study, we observed that a beneficial effects
of the combination of NPB with CHL, KAN as well as
that of compound 4 with STR and CIP in all tested bac-
teria were achieved. Synergistic or modulating effects of
NPB and 4 with other antibiotics were noted on more
than 70 % of the tested MDR bacteria in several case
(Tables 3 and 4), suggesting that they can act as efflux
pump inhibitors [40]. This is strenghten by the fact that
no synergistic effect was obtained with beta-lactamines
(CEF and AMP) in the preliminary test (Additional
file 1: Tables S2 and S3), as their target are located in
the bacterial coat and hence, are not generally affected by
AcrAB-TolC and MexAB-OprM efflux pumps in Entero-
bacteriaceae and P. aeruginosa respectively [4].
This is the first time to report the potential of NPB to
prevent the proliferation of MDR Gram-negative
bacterial as well as to reverse antibiotic resistance in
MDR bacteria. However, the methanol extract from
roots of Nauclea pobeguinii showed synergistic effects
with ampicillin and amoxicillin against Staphylococcus
aureus and drug-sensitive Klebsiella pneumoniae [43].
The present study therefore provides additional informa-
tion on the ability of other parts of Nauclea pobeguinii
to potentiate the activity of antibiotics. Though, the anti-
bacterial potential of compound 4 is well known [44],
the present study also identify this stilbene as the potent
antibacterial constituent of Nauclea pobeguiinii. This
study also provides more information on its inhibitory
potential against MDR bacteria expressing active efflux
pumps as well as it ability to potentiate the activity of
antibiotics.
Conclusion
The results reported herein are very interesting, in
regards to the medical importance of the studied micro-
organisms. These data provide evidence that crude ex-
tracts and compounds from Nauclea pobeguinii and
mostly the bark extract (NPB) and compound 4 are po-
tential sources of compounds to fight MDR bacterial
species. The bark extract and 4 could also be used in
combination with antibiotics to overcome bacterial
resistance.
Table 4 MIC of antibiotics after the association of resveratrol (4) at MIC/2 and MIC/4 against selected MDR bacteria
Antibioticsa Concentration
of 4
Bacteria strainsb, MIC of antibiotics alone and in presence of 4 (Resveratrol), FIC (in bracket ) PBSS (%)c
PA124 CM64 KP55 AG102 AG100Atet PS2636
CHL 0 256 128 32 64 64 256
MIC/2 32 (0.25)S 2(0.02)S 16(0.5)S 64(1)I <2(<0.03)S 64(0.25)S 5/6 (83.3 %)
MIC/4 32(0.25)S 4(0.03)S 16(0.5)S 64(1)I <2 (<0.03)S 64(0.25)S 5/6(83.3 %)
KAN 0 128 64 64 4 32 4
MIC/2 64(0.5)S <2 (<0.03)S 32(0.5)S <2 (<0.5)S <2(0.06)S 4(1)I 5/6(83.3 %)
MIC/4 64(0.5)S <2 (<0.03)S 32(0.5)S <2 (<0.5)S <2(0.06)S 4(1)I 5/6(83.3 %)
STR 0 64 128 64 ≤2 − ≤2
MIC/2 32(0.5)S 64(0.5)S 16(0.25)S <2 na 64(≤0.5)S <2 na 4/4 (100 %)
MIC/4 32(0.5)S 64(0.5)S 32(0.5)S 4(>2) na 128(≤0.5)S <2 na 4/4 (100 %)
CIP 0 64 8 4 1 64 4
MIC/2 4(0.06)S <2(0.25)S <2(<0.5)S <0.5(<0.5)S <2(<0.03)S 8(2)I 5/6(83.3 %)
MIC/4 16(0.25)S <2(0.25)S <2(<0.5)S <0.5(<0.5)S <2(<0.03)S <0.5(<0.13)S 6/6 (100 %)
TET 0 64 64 32 4 256 64
MIC/2 4(0.06)S 64(1)I 32(1)I <2(<0.5)S 256(1)I 32(0.5)S 3/6 (50 %)
MIC/4 4(0.06)S 128(2)I 16(0.5)S <2(<0.5)S 256(1)I 16(0.25)S 4/6 (66.7 %)
(−): >256 μg/mL; 0: without compound 4 (only antibiotic tested). CIP have been tested at 64 μg/ml on AG102 and PS2636; na: non-applicable; Values in bold: MIC
of antibiotic alone or significant synergistic effects
S Synergy, I Indifference, A Antagonism, P product, FIC fractional inhibitory concentration
aAntibiotics [CHL: chloramphenicol, KAN : kanamycin, STR: streptomycin, CIP : ciprofloxacin, TET : tetracycline]
bBacterial strains: Escherichia coli [ AG102, AG100Atet], Pseudomonas aeruginosa [PA124], Enterobacter aerogenes [CM64], Klebsiella pneumoniae [KP55], Providencia
stuartii [PS2636]
cPBSS: percentage of bacteria strain on which synergism has been observed
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Additional file
Additional file 1: Table S1. Bacterial strains used and their features.
Table S2. Preliminary assay of extracts from bark and leaves of Nauclea
pobeguinii in combination with commonly used antibiotics against
PA124. Table S3. Preliminary assay with compounds in combination with
commonly used antibiotics against PA124. (DOC 173 kb)
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ester; 3, resveratrol; 4, resveratrol β-D-glucopyranoside; 6, strictosamide; AMP,
ampicillin; ATCC, American Type Culture Collection; CEF, cefepime; CHL,
chloramphenicol; CIP, ciprofloxacin; EPI, efflux pump inhibitors; FIC,
fractional inhibitory concentration; HNC, National Herbarium of
Cameroon; INT, p-iodonitrotetrazolium chloride; KAN, kanamycin; MBC,
minimal bactericidal concentrations; MDR, multidrug resistant; MDRGN,
multidrug resistant Gram-negative; MeOH, methanol; MIC, minimal inhibitory
concentrations; NPB, Nauclea pobeguiinii bark; NPL, Nauclea pobeguiinii leaves;
RA, reference antibiotics; RND, resistance–nodulation–cell division; STR,
streptomycin; TET, Tetracycline.
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